HC Wainwright & Co. Reiterates Buy on AcelRx Pharmaceuticals, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on AcelRx Pharmaceuticals (NASDAQ:ACRX) and maintained a price target of $5.
December 07, 2023 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on AcelRx Pharmaceuticals and maintained a price target of $5.
The reiteration of a Buy rating and the maintenance of a $5 price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on ACRX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100